Literature DB >> 31521847

Aggressive posterior retinopathy of prematurity in two cohorts of patients in South India: implications for primary, secondary, and tertiary prevention.

Parag K Shah1, Prema Subramanian1, Narendran Venkatapathy1, Robison Vernon Paul Chan2, Michael F Chiang3, John Peter Campbell4.   

Abstract

BACKGROUND: Aggressive posterior retinopathy of prematurity (APROP), which has a poor visual prognosis, is common in low- and middle-income countries (LMICs) as a result of suboptimal oxygen monitoring (primary prevention). The purpose of this study was to compare outcomes in APROP eyes treated with laser to eyes treated with antivascular endothelial growth factor (anti-VEGF) therapy.
METHODS: The medical records of a cohort of APROP eyes treated with anti-VEGF (2010-2018) and another of eyes treated with laser photocoagulation (2002-2010) at the same institution in South India were reviewed retrospectively and compared. The main outcome was the proportion of eyes developing retinal detachment during resolution of acute ROP.
RESULTS: A total of 398 eyes of 199 preterm babies with APROP were included: 168 eyes were treated with photocoagulation; 230, with anti-VEGF. From 2002 to 2010, compared to the more recent cohort, babies diagnosed with APROP tended to be heavier (P < 0.001), older (P < 0.001), and exposed to fewer days of oxygen (P = 0.02). In the laser-treated cohort, 17 of 168 eyes (10%) developed retinal detachment (7, stage 5; 12, stage 4), compared with 3 of 230 (1%) in the anti-VEGF cohort (all stage 4 [P = 0.002]).
CONCLUSIONS: The incidence of retinal detachment was significantly lower in eyes treated with anti-VEGF compared with laser-.treated eyes In the absence of a randomized trial, these data suggest that anti-VEGF may lead to better anatomic outcomes, although questions remain concerning dosage, timing, and risks.
Copyright © 2019 American Association for Pediatric Ophthalmology and Strabismus. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31521847      PMCID: PMC7219568          DOI: 10.1016/j.jaapos.2019.05.014

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  12 in total

Review 1.  The International Classification of Retinopathy of Prematurity revisited.

Authors: 
Journal:  Arch Ophthalmol       Date:  2005-07

2.  Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.

Authors:  Huseyin Yetik; Murat Gunay; Sarkis Sirop; Ziya Salihoglu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-12-14       Impact factor: 3.117

3.  Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.

Authors:  Helen A Mintz-Hittner; Megan M Geloneck; Alice Z Chuang
Journal:  Ophthalmology       Date:  2016-05-27       Impact factor: 12.079

4.  Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1988-04

5.  Aggressive posterior retinopathy of prematurity in large preterm babies in South India.

Authors:  Parag K Shah; Venkatapathy Narendran; Narendran Kalpana
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2012-05-18       Impact factor: 5.747

6.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.

Authors:  Helen A Mintz-Hittner; Kathleen A Kennedy; Alice Z Chuang
Journal:  N Engl J Med       Date:  2011-02-17       Impact factor: 91.245

7.  Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

Authors: 
Journal:  Arch Ophthalmol       Date:  2003-12

8.  OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURITY IN ZONE I.

Authors:  Je Moon Yoon; Dong Hoon Shin; Sang Jin Kim; Don-Il Ham; Se Woong Kang; Yun Sil Chang; Won Soon Park
Journal:  Retina       Date:  2017-01       Impact factor: 4.256

9.  Vascular changes on fluorescein angiography of premature infants with low risk of retinopathy of prematurity after high oxygen exposure.

Authors:  Maria Ana Martinez-Castellanos; Raul Velez-Montoya; Kenneth Price; Andree Henaine-Berra; Gerardo García-Aguirre; Virgilio Morales-Canton; Linda Alejandra Cernichiaro-Espinosa
Journal:  Int J Retina Vitreous       Date:  2017-01-16

10.  Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.

Authors:  Qizhe Tong; Hong Yin; Mingwei Zhao; Xiaoxin Li; Wenzhen Yu
Journal:  BMC Ophthalmol       Date:  2018-06-26       Impact factor: 2.209

View more
  6 in total

Review 1.  Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.

Authors:  Georgios N Tsiropoulos; Aikaterini K Seliniotaki; Anna-Bettina Haidich; Nikolaos Ziakas; Asimina Mataftsi
Journal:  Int Ophthalmol       Date:  2022-10-10       Impact factor: 2.029

2.  Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity.

Authors:  Rania M Bassiouny; Walid M Gaafar; Amgad El Nokrashy; Ameera G Abdelhameed; Eman A Attallah; Ahmed G Elgharieb; Mohamed R Bassiouny
Journal:  Eye (Lond)       Date:  2021-10-28       Impact factor: 4.456

3.  Aggressive Posterior Retinopathy of Prematurity: Clinical and Quantitative Imaging Features in a Large North American Cohort.

Authors:  Kellyn N Bellsmith; James Brown; Sang Jin Kim; Isaac H Goldstein; Aaron Coyner; Susan Ostmo; Kishan Gupta; R V Paul Chan; Jayashree Kalpathy-Cramer; Michael F Chiang; J Peter Campbell
Journal:  Ophthalmology       Date:  2020-02-07       Impact factor: 12.079

4.  Applications of Artificial Intelligence for Retinopathy of Prematurity Screening.

Authors:  J Peter Campbell; Praveer Singh; Travis K Redd; James M Brown; Parag K Shah; Prema Subramanian; Renu Rajan; Nita Valikodath; Emily Cole; Susan Ostmo; R V Paul Chan; Narendran Venkatapathy; Michael F Chiang; Jayashree Kalpathy-Cramer
Journal:  Pediatrics       Date:  2021-03       Impact factor: 7.124

5.  Aggressive Posterior Retinopathy of Prematurity: Long-Term Outcomes Following Intravitreal Bevacizumab.

Authors:  Ameay V Naravane; Peter J Belin; Shaina Rubino; Polly A Quiram
Journal:  Front Pediatr       Date:  2022-02-11       Impact factor: 3.418

6.  Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.

Authors:  Gerard P Barry; Yinxi Yu; Gui-Shuang Ying; Lauren A Tomlinson; Juliann Lajoie; Marilyn Fisher; Gil Binenbaum
Journal:  Ophthalmology       Date:  2020-12-31       Impact factor: 14.277

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.